Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 in relapsed small cell lung cancer
NCT07189455Phase 3Recruiting
- Sponsor
- Zelgen
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 3 trial of alveltamig in small cell lung cancer (SCLC), sponsored by Zelgen. Started Dec 2025; status: recruiting.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07189455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189455.